3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
2571
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2086
Lymphoma, Non-Hodgkin
2058
Leukemia, Lymphocytic, Chronic, B-Cell
1771
Lymphoma, Follicular
1652
Lymphoma, Large B-Cell, Diffuse
1597
Leukemia
1172
Hodgkin Disease
1128
Lymphoma, Mantle-Cell
1110
Burkitt Lymphoma
887
Leukemia, Myeloid, Acute
885
Lymphoma, B-Cell, Marginal Zone
788
Recurrence
779
Multiple Myeloma
744
Lymphoma, B-Cell
704
Myelodysplastic Syndromes
615
Neoplasms
494
Lymphoma, T-Cell, Cutaneous
479
Waldenstrom Macroglobulinemia
470
Lymphoma, Large-Cell, Immunoblastic
456
Mycosis Fungoides
383
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
382
Lymphoma, Large-Cell, Anaplastic
362
Sezary Syndrome
321
Lymphoma, T-Cell, Peripheral
321
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
307
Hematologic Neoplasms
299
Myeloproliferative Disorders
288
Neoplasms, Plasma Cell
270
Blast Crisis
261
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Purpura, Thrombotic Thrombocytopenic
×
Lymphoid
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn